Reinforced Leadership by Dxcover through the addition of elite scientific advisors and board members of international repute.
Dxcover Strengthens Leadership with New Appointments
Dxcover, a pioneering company in oncology diagnostics, has made significant strides in expanding its leadership team. The company has recently appointed new members to both its Scientific Advisory Board (SAB) and Board of Directors, bringing together a diverse group of experts in neurology, gynaecological oncology, clinical research, commercial diagnostics, artificial intelligence, and oncology.
The latest additions to Dxcover's SAB include Professor Katy Peters, MD PhD, an expert in neurology and neurosurgery from Duke University Medical Center, and Professor Emma Crosbie, MBChB(Hons) PhD MRCOG, a gynaecological oncology specialist from The University of Manchester. Professor Peters brings deep knowledge of brain cancer care pathways and translational research, while Professor Crosbie is renowned for her work in early detection and prevention of endometrial and ovarian cancers.
The search results also mention a third SAB member, although their name is not explicitly provided. These SAB members are set to drive Dxcover’s next phase of clinical translation and commercial growth.
Regarding the Board of Directors, the recent appointments reinforce the company’s leadership with complementary expertise in clinical statistics, AI, and oncology, although specific newly appointed board members’ names and roles are not detailed in the available results.
In addition to the SAB appointments, Dxcover has appointed two new Non-Executive Directors for its US expansion and revenue-stage growth. Stacy Chick, an experienced global commercial life sciences executive, is one of these new directors. Chick developed markets, built commercial operations, and scaled revenues at optimal reimbursement rates, and has advised Dxcover since 2021.
Marc Jones, with over 25 years of experience as a health technology executive, is another new Non-Executive Director. Jones has led multiple FDA-cleared and CE-marked products to development, approval, and commercial scale-up. He currently leads the development of digital biomarkers for neurological diseases using artificial intelligence and real-world data at Altoida.
In a statement, Professor Matthew J. Baker, CEO and inventor of Dxcover, said that the new scientific and commercial leaders will be instrumental in expanding access to Dxcover's platform, broadening its diagnostic menu, pursuing regulatory milestones, and delivering the technology into the hands of physicians and patients globally.
Dxcover's latest appointments also include Professor William E. Fisher MD FACS, a pancreatic surgery and oncology expert from Baylor College of Medicine, and Dr. Luke Pike MD DPhil, a radiation oncologist specializing in CNS malignancies from Memorial Sloan Kettering Cancer Center. Both have been appointed to Dxcover's SAB.
Stacy Chick's extensive experience in taking diagnostic innovations from research to commercial stage, particularly at Inivata and Kiyatec, will undoubtedly prove invaluable in Dxcover's mission to revolutionize oncology diagnostics. The company's focus on brain, gynaecological, and pancreatic cancers, combined with its integration of artificial intelligence and commercial strategy, positions it well for future success.
References: [1] [Source] [5] [Source]
- Dxcover's Scientific Advisory Board expansion includes Professor Katy Peters, a neurology expert from Duke University Medical Center, and Professor Emma Crosbie, a gynaecological oncology specialist from The University of Manchester.
- These new SAB members will drive Dxcover’s next phase of clinical translation and commercial growth.
- Stacy Chick, an experienced global commercial life sciences executive, has joined Dxcover's Board of Directors as a Non-Executive Director, focusing on the company's US expansion and revenue-stage growth.
- Dr. Luke Pike, a radiation oncologist specializing in CNS malignancies from Memorial Sloan Kettering Cancer Center, has also been appointed to Dxcover's SAB.
- As Dxcover continues to grow, it will leverage the expertise of its new leadership in digital health, health tech, artificial intelligence, and scientific research to revolutionize oncology diagnostics.
- Meanwhile, strategic investments and financial planning will play a crucial role in the success of this innovative business, involving areas such as personal finance, finance, and investing.
